Sequential treatment with doxorubicin and zoledronic acid has no additive effects in an aggressive model of established bone metastases

Abstract

Aim: Bisphosphonates are used as an adjuvant treatment in breast cancer bone metastasis patients, often simultaneously with chemotherapeutic agents. Interestingly, their sequential combination has been reported to have synergistic anti-tumor effects on bone metastases in preclinical models. We studied the effects of doxorubicin (DOX) and zoledronic acid (ZOL) and their combination on established bone metastases in the MDA-MB-231(SA)GFP bone metastasis model.

Methods: Tumor burden and osteolytic bone lesions were quantitated by fluorescence imaging and radiography, respectively. The mice were randomized in four groups receiving vehicle, DOX, ZOL or both DOX and ZOL in a sequential combination on day 14. Serum marker of osteoclast number was followed weekly, and blood ionized calcium was measured at sacrifice. Bone and tumor area, apoptosis and proliferation of tumor cells were analyzed from histological sections.

Results: ZOL prevented hypercalcemia and osteolytic lesion progression, whereas DOX induced apoptosis in the MDA-MB-231(SA)GFP cells. However, neither of the treatments alone nor in sequential combination were able to reduce tumor burden in bone. Furthermore, no additive effects on tumor cell apoptosis were observed in the combination group.

Conclusion: No additive effects in combination of DOX and ZOL were observed in this aggressive model of breast cancer bone metastasis.

Keywords

Combination treatment / breast cancer / bone metastasis / MDA-MB-231(SA) / doxorubicin / zoledronic acid

References

[1] Wilson C.Adjuvant bone-targeted therapies for postmenopausal breast cancer..JAMA Oncol2016;2:423-4

[2] Body JJ,Tombal B,Arif A.Bone health in the elderly cancer patient: a SIOG position paper..Cancer Treat Rev2016;51:46-53

[3] Wong M.Optimal management of bone metastases in breast cancer patients..Breast Cancer (Dove Med Press)2011;3:35-60 PMCID:PMC3846421

[4] Coleman R,Dodwell D,Wilson C.Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial..Lancet Oncol2014;15:997-1006

[5] Daubiné F,Gasser J,Clézardin P.Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis..J Natl Cancer Inst2007;99:322-30

[6] Hiraga T,Mundy GR.The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases..Cancer Res2001;61:4418-24

[7] Zekri J,Karim SM.The anti-tumour effects of zoledronic acid..J Bone Oncol2014;3:25-35 PMCID:PMC4723416

[8] Suominen MI,Käkönen R,Alhoniemi E.Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis..J Natl Cancer Inst2013;105:908-16

[9] Junankar S,Jurczyluk J,Down J.Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer..Cancer Discov2015;5:35-42 PMCID:PMC4293349

[10] Rogers TL,Hughes R,Brown HK.Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models..Cell Oncol (Dordr)2013;36:505-14

[11] Ottewell PD,Mönkkönen H,Coleman RE.Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo..Clin Cancer Res2008;14:4658-66

[12] Brown HK,Evans CA,Holen I.A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts..J Bone Oncol2012;1:47-56 PMCID:PMC4723328

[13] Ottewell PD,Jones M,Coleman RE.Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer..J Natl Cancer Inst2008;100:1167-78

[14] Ottewell PD,Lefley DV,Coleman RE.Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone..Mol Cancer Ther2009;8:2821-32

[15] Ottewell PD,Cross SS,Coleman RE.Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model..Int J Cancer2010;126:522-32

[16] Guise TA,Taylor SD,Dallas M.Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis..J Clin Invest1996;98:1544-9 PMCID:PMC507586

[17] Arguello F,Baggs RB.Experimental bone and bone marrow metastasis in laboratory animals..J Natl Cancer Inst1990;82:1069-70

[18] Sasaki A,Story B,Chapman M.Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice..Cancer Res1995;55:3551-7

[19] Hirbe AC,Floyd DH,Becker SN.The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts..Bone2009;44:908-16 PMCID:PMC2782613

[20] Coleman RE,Cameron D,Dodwell D.The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer..Br J Cancer2010;102:1099-105 PMCID:PMC2853093

[21] Horiguchi J,Miura D,Hayashi M.A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer..J Clin Oncol2013;31:1029

[22] Fasching PA,Hauschild M,Schütte M.FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients..BMC Cancer2014;14:66 PMCID:PMC3937056

[23] Charehbili A,Smit VT,Hamdy NA.Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)..Ann Oncol2014;25:998-1004

[24] Green JR.Antitumor effects of bisphosphonates..Cancer2003;97:840-7

[25] Käkönen RS,Suominen MI.Quantitative image analysis method for measuring whole-body tumor burden in a mouse model of breast cancer bone metastasis..J Bone Miner Res2008;23:S136-243

[26] Kang Y,Shu W,Kakonen SM.A multigenic program mediating breast cancer metastasis to bone..Cancer Cell2003;3:537-49

[27] Pollari S,Edgren H,Kohonen P.Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis..Breast Cancer Res Treat2011;125:421-30

[28] Pollari S,Perälä M,Käkönen SM.Identification of microRNAs inhibiting TGF-β-induced IL-11 production in bone metastatic breast cancer cells..PLoS One2012;7:e37361 PMCID:PMC3357420

[29] Heymann D.Bone cancer: primary bone cancers and bone metastases.2015;2th edAmsterdamElsevier/Academic Press486

[30] Gregory PA,Paterson EL,Tsykin A.The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1..Nat Cell Biol2008;10:593-601

[31] Haider MT,Dear TN,Brown HK.Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis..Bone2014;66:240-50 PMCID:PMC4127787

[32] Lv Y,Xu W,Lv X.Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 264.7 cells treated with receptor-activated nuclear κB ligand..Exp Ther Med2015;9:143-6